Condition: Melanoma, Cutaneous Malignant · Sponsor: Immatics US, Inc.
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma. For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/
This description comes directly from the study's public registry record.
Immatics US, Inc. · +1 346 204-5400 · ctgovinquiries@immatics.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Phoenix, Arizona, United States | Recruiting |
| Honor Health Research Institute | Scottsdale, Arizona, United States | Recruiting |
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| UCLA Hematology/Oncology | Los Angeles, California, United States | Recruiting |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | Recruiting |
| Stanford Cancer Center | Stanford, California, United States | Recruiting |
| University of Colorado, Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Mayo Clinic Florida | Jacksonville, Florida, United States | Active Not Recruiting |
| University of Miami - Sylvester Comprehensive Cancer Cente | Miami, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
+ 54 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06743126